daunorubicin
1 clinical trial
3 abstracts
4 indications
Indication
Acute Myeloid LeukemiaAbstract
Evaluation of the toxicity and outcomes of the combination of midostaurin and CLAG-M in patients with FLT3-mutated acute myeloid leukemia (AML): A multi-center retrospective analysis.Org: University of Washington/Fred Hutchison Cancer Center,
Abstract
Treatment discontinuation due to toxicity for patients with acute myeloid leukemia (AML) treated on SWOG S1203.Org: University of Washington/Fred Hutchinson Cancer Center, University of Washington/Fred Hutchinson Cancer Center and SWOG Statistics and Data Management Center, Seattle, WA, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Duke Cancer Institute, Duke University Medical Center, Durham, NC,
Clinical trial
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 MutationStatus: Active (not recruiting), Estimated PCD: 2018-12-13
Abstract
Cardiotoxicity of CPX-351 vs 7+3 in patients with untreated high-risk acute myeloid leukemia.Org: Cardio-Oncology Center of Excellence, Washington University School of Medicine, St. Louis, MO, Heart and Vascular Institute, Penn State Hershey Medical Center, Hershey, PA, Jazz Pharmaceuticals, Philadelphia, PA, Jazz Pharmaceuticals, Palo Alto, CA, Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas, Kansas City, KS,